QIAGEN CLC Genomics

CRISPR data analysis and interpretation using QIAGEN Ingenuity Pathway Analysis and CLC Genomics Workbench

1,005 views
May 10, 2022
CRISPR high-throughput sequencing data analysis and pathway interpretation are of great interest to many researchers. Therefore, QIAGEN Digital Insights is hosting this 90-minute training focused on analyzing CRISPR high-throughput sequencing data using QIAGEN CLC Genomics Workbench and interpreting the gene list generated by sequencing data or CRISPR screening using QIAGEN IPA.

Attendees will learn how to use QIAGEN CLC Genomics Workbench to:
• Import sequencing reads (ex. FASTQ format)
• Run reads through a pipeline (e.g., RNA-seq, DNA-seq, etc.)
• Generate and export downstream results (heatmap, differential expression table, genome browser view and more)

Attendees will learn how to use QIAGEN IPA to:
• Study the impact of CRISPR editing on key pathways and regulators
• Compare different CRISPR-modulated biological systems
• Identify a list of regulators and biomarkers specific to conditions of interest
• Export results in the form of high-quality images and tables

Speaker: Araceli Cuellar, Ph.D., Field Application Scientist, QIAGEN Digital insights

Related videos

QIAGEN CLC Genomics

Single-cell RNA-seq: Analysis and interpretation of user and public data - May 20 2021

920 views May 21, 2021

In this 90-minute training, attendees will learn how to analyze and interpret...

QIAGEN CLC Genomics

Long reads analysis using QIAGEN CLC Genomics workbench (with new features - 2024)

3 views February 20, 2024

This webinar will introduce users to the long read support plugin for Oxford...

QIAGEN CLC Genomics

What’s new in QIAGEN CLC Genomics Workbench version 24

78 views January 31, 2024

QIAGEN CLC Genomics Workbench version 24 is here with exciting updates we'd...

QIAGEN CLC Genomics

Circulating Tumor Cell Detection and Analysis to Support Malignancy Designation, Tumor-of-Origin...

140 views October 25, 2023

Circulating tumor cells (CTCs) are cells that leave the primary tumor and are...